Cargando…

A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside

The prototypes and metabolites formed from the use of traditional Chinese medicines (TCM) are typically the cause of both side side-effects and therapeutic results. Therefore, the characterization of in vivo substances and the determination of functional changes are of great importance for clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fengxiang, Cui, ShuangShuang, Li, Ziting, Yuan, Yulinlan, Li, Chang, Li, Ruiman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056848/
https://www.ncbi.nlm.nih.gov/pubmed/35514403
http://dx.doi.org/10.1039/d0ra06382g
_version_ 1784697758795431936
author Zhang, Fengxiang
Cui, ShuangShuang
Li, Ziting
Yuan, Yulinlan
Li, Chang
Li, Ruiman
author_facet Zhang, Fengxiang
Cui, ShuangShuang
Li, Ziting
Yuan, Yulinlan
Li, Chang
Li, Ruiman
author_sort Zhang, Fengxiang
collection PubMed
description The prototypes and metabolites formed from the use of traditional Chinese medicines (TCM) are typically the cause of both side side-effects and therapeutic results. Therefore, the characterization of in vivo substances and the determination of functional changes are of great importance for clinical applications. Secoisolariciresinol-diglycoside (SDG), one major compound in flaxseeds, was used as a potential drug to treat tumors in the clinic; however, the metabolism information and functional changes of SDG in vivo were limited, which limited its application. In this study, an integrated strategy based on metabolite profiling and network pharmacology was applied to explore the metabolism feature and functional changes of SDG. As a result, a total of 28 metabolites were found in rats, including 14 in plasma, 22 in urine, 20 in feces, 7 in the heart, 14 in the liver, 8 in the spleen, 10 in the lungs, 14 in the kidneys, and 4 in the brain. Among them, M8, M13 and M26 were the main metabolites of SDG in rats and 24 were characterized for the first time. The metabolic reactions contained phase I reactions of demethylation, dehydroxylation, deglycosylation, arabinosylation and glycosylation, and phase II reactions of glucuronidation and sulfation were also observed. Notably, the arabinosylation and glycosylation were found in SDG for the first time. Meanwhile, 121 targets of SDG and its metabolites were found, PRKCB was the main target of SDG, and the metabolites of SDG mainly targeted HSP90A1, IL6, AKT1, MAPK3, MTOR, PIK3CA, SRC, ESR1, AR, PIK3CB, and PIK3CB. The difference of targets between SDG and its metabolites could result in its additional functional pathways of neurotrophin signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway or indications of anti-prostate cancer. This work provided a new insight for exploring the mechanism and therapy indications of drugs.
format Online
Article
Text
id pubmed-9056848
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90568482022-05-04 A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside Zhang, Fengxiang Cui, ShuangShuang Li, Ziting Yuan, Yulinlan Li, Chang Li, Ruiman RSC Adv Chemistry The prototypes and metabolites formed from the use of traditional Chinese medicines (TCM) are typically the cause of both side side-effects and therapeutic results. Therefore, the characterization of in vivo substances and the determination of functional changes are of great importance for clinical applications. Secoisolariciresinol-diglycoside (SDG), one major compound in flaxseeds, was used as a potential drug to treat tumors in the clinic; however, the metabolism information and functional changes of SDG in vivo were limited, which limited its application. In this study, an integrated strategy based on metabolite profiling and network pharmacology was applied to explore the metabolism feature and functional changes of SDG. As a result, a total of 28 metabolites were found in rats, including 14 in plasma, 22 in urine, 20 in feces, 7 in the heart, 14 in the liver, 8 in the spleen, 10 in the lungs, 14 in the kidneys, and 4 in the brain. Among them, M8, M13 and M26 were the main metabolites of SDG in rats and 24 were characterized for the first time. The metabolic reactions contained phase I reactions of demethylation, dehydroxylation, deglycosylation, arabinosylation and glycosylation, and phase II reactions of glucuronidation and sulfation were also observed. Notably, the arabinosylation and glycosylation were found in SDG for the first time. Meanwhile, 121 targets of SDG and its metabolites were found, PRKCB was the main target of SDG, and the metabolites of SDG mainly targeted HSP90A1, IL6, AKT1, MAPK3, MTOR, PIK3CA, SRC, ESR1, AR, PIK3CB, and PIK3CB. The difference of targets between SDG and its metabolites could result in its additional functional pathways of neurotrophin signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway or indications of anti-prostate cancer. This work provided a new insight for exploring the mechanism and therapy indications of drugs. The Royal Society of Chemistry 2020-09-21 /pmc/articles/PMC9056848/ /pubmed/35514403 http://dx.doi.org/10.1039/d0ra06382g Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Zhang, Fengxiang
Cui, ShuangShuang
Li, Ziting
Yuan, Yulinlan
Li, Chang
Li, Ruiman
A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title_full A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title_fullStr A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title_full_unstemmed A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title_short A combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
title_sort combination of metabolite profiling and network pharmacology to explore the potential pharmacological changes of secoisolariciresinol-diglycoside
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056848/
https://www.ncbi.nlm.nih.gov/pubmed/35514403
http://dx.doi.org/10.1039/d0ra06382g
work_keys_str_mv AT zhangfengxiang acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT cuishuangshuang acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT liziting acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT yuanyulinlan acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT lichang acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT liruiman acombinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT zhangfengxiang combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT cuishuangshuang combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT liziting combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT yuanyulinlan combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT lichang combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside
AT liruiman combinationofmetaboliteprofilingandnetworkpharmacologytoexplorethepotentialpharmacologicalchangesofsecoisolariciresinoldiglycoside